晚期/转移性食管胃腺癌免疫治疗的最新进展与当前挑战
综述总结免疫检查点抑制剂在晚期/转移性食管胃腺癌中的最新获批情况与相关II/III期试验结果。基于CHECKMATE-649、KEYNOTE-590、KEYNOTE-811、ATTRACTION-02和KEYNOTE-059等研究,纳武利尤单抗、帕博利珠单抗联合化疗或单药在不同治疗线及PD-L1 CPS、MSI状态等生物标志物条件下获批,免疫耐药与性别对疗效的影响尚待明确。
要点
- 基于CHECKMATE-649,纳武利尤单抗联合化疗获批用于PD-L1 CPS≥5的晚期GEJC、EC和GC一线治疗。
- 基于KEYNOTE-590,帕博利珠单抗联合化疗获批用于晚期GEJC和EC,欧洲要求CPS≥10。
- Her2阳性患者中曲妥珠单抗联合一线化疗加帕博利珠单抗有获益应答率,并在美国获批。
核心结论
- 免疫治疗新时代已成功应用于转移性/局部晚期食管胃腺癌的治疗,免疫检查点抑制剂在几乎每个治疗线均丰富了治疗选择。
- 免疫治疗耐药问题及性别对免疫检查点抑制剂应答的影响尚需明确。
研究设计与样本
- 综述,概述免疫检查点抑制剂在晚期食管胃腺癌中的当前获批情况,并汇总相关II/III期试验结果。
主要发现
- 基于CHECKMATE-649,纳武利尤单抗联合化疗在PD-L1阳性晚期GEJC、EC和GC一线治疗中获批,欧洲用于PD-L1 CPS≥5患者,美国和亚洲不依赖PD-L1评分。
- 基于KEYNOTE-590,晚期GEJC和EC患者符合帕博利珠单抗联合化疗条件,欧洲要求CPS≥10,美国无此限制。
- Her2阳性患者中,曲妥珠单抗联合一线化疗加帕博利珠单抗有获益的应答率,并在美国获批(KEYNOTE-811)。
- 三线治疗中,纳武利尤单抗给药获得更优总生存(日本获批,ATTRACTION-02),帕博利珠单抗对缓解持续时间有正面影响(KEYNOTE-059)。
关键数值与推荐
- CHECKMATE-649:纳武利尤单抗联合化疗一线治疗PD-L1阳性晚期GEJC、EC和GC,欧洲获批用于PD-L1 CPS≥5患者,美国和亚洲不依赖PD-L1评分。
- KEYNOTE-590:帕博利珠单抗联合化疗用于晚期GEJC和EC,欧洲获批用于CPS≥10患者,美国获批。
- KEYNOTE-811:Her2阳性患者中曲妥珠单抗联合一线化疗加帕博利珠单抗有获益应答率,美国获批。
- ATTRACTION-02:三线治疗中纳武利尤单抗给药获得更优总生存,日本获批。
- KEYNOTE-059:帕博利珠单抗对缓解持续时间有正面影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 免疫治疗耐药问题尚需明确。
- 性别对免疫检查点抑制剂应答的影响尚需明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The new era of immunotherapy is successfully implemented in the treatment of metastatic/locally advanced esophagogastric adenocarcinoma (EGAC), as it has been investigated in combinations with/without chemotherapy in human epidermal growth factor receptor 2 (Her2)-positive and Her2-negative tumors. Recent approvals of immune checkpoint inhibitors (ICI) enrich the therapeutic landscape in nearly every therapeutic line. Based on CHECKMATE-649, the combination of nivolumab and chemotherapy in first-line therapy of programmed cell death protein 1 (PD-L1)-positive patients with advanced gastroesophageal junction cancer (GEJC), esophageal cancer (EC), and gastric cancer (GC) was approved in Europe for PD-L1 combined positivity score (CPS) ≥ 5 patients and independently from PD-L1 score in the USA and Asia. Based on KEYNOTE-590, patients with advanced GEJC and EC qualify for the combination of pembrolizumab plus chemotherapy in Europe (CPS ≥ 10) and the USA. For Her2-positive patients, trastuzumab with first-line chemotherapy plus pembrolizumab has beneficial response rates and resulted in approval in the USA (KEYNOTE-811). In third-line therapy, superior overall survival (OS) was achieved by the administration of nivolumab (approval in Japan, ATTRACTION-02), and pembrolizumab shows a positive effect on the duration of response (KEYNOTE-059). Questions of resistance to immunotherapy or the role of gender in response to ICI need to be clarified. This review provides an overview of the current approvals of ICI in advanced EGAC and reflects results of relevant phase II/III trials with focus on possible biomarkers, including PD-L1 CPS and microsatellite-instability (MSI) status.
引用
- Moehler M, Högner A, Wagner AD, et al. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. Eur J Cancer. 2022. PMID: 36183651. doi:10.1016/j.ejca.2022.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。